The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation

Europace

Volumn 13, Issue 4, 2011, Pages 451-452

  Goette, Andreas ^a  

^a St Vincenz Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN II ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CANDESARTAN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LISINOPRIL; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; DIABETES MELLITUS; EDITORIAL; ELECTROCARDIOGRAPHY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SECONDARY PREVENTION;

AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; COMORBIDITY; HUMANS; HYPERTENSION; PREVALENCE; TETRAZOLES; TREATMENT OUTCOME;

EID: 79953798751     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur045     Document Type: Editorial

References (12)

1. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-9. (Pubitemid 40789940)
2. Goette A, Staack T, Röcken C, Arndt M, Geller JC, Huth C et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77. (Pubitemid 30307515)
3. Goette A, Arndt M, Röcken C, Spiess A, Staack T, Geller JC et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000;101:2678-81.
4. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41:2197-204. (Pubitemid 36724267)
5. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition: a meta-analysis. J Am Coll Cardiol 2010;55:2299-307.
6. Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II Study). Europace 2011;13:473-79.
7. Investigators G-A. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009;360:1606-17.
8. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009;54;2023-31.
9. Goette A, Breithardt G, Fetsch T, Hanrath P, Klein HU, Lehmacher W et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial: rationale and study design. Clin Drug Invest 2007;27:697-705. (Pubitemid 47481702)
10. Goette A, Schön A, Kirchhof P, Breithardt G, Klein HU, Steinbeck G et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial. Hotline III ESC 2010. p3772.
11. Goette A, Bukowska A, Lendeckel U, Erxleben M, Hammwöhner M, Strugala D et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 2008;117:732-42. (Pubitemid 351640674)
12. Goette A, Bukowska A, Dobrev D, Pfeiffenberger J, Morawietz H, Strugala D et al. Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J 2009;30:1411-20.